• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.头孢他啶/他唑巴坦：治疗复杂性革兰氏阴性菌感染的新选择。
P T. 2014 Dec;39(12):825-32.
2
Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection.头孢洛扎/他唑巴坦单剂静脉给药在确诊或疑似革兰氏阴性感染的儿童中的药代动力学和安全性。
Pediatr Infect Dis J. 2018 Nov;37(11):1130-1136. doi: 10.1097/INF.0000000000002170.
3
Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.头孢洛扎/他唑巴坦3期试验中糖尿病合并腹腔内感染或复杂性尿路感染患者的分析。
BMC Infect Dis. 2017 May 2;17(1):316. doi: 10.1186/s12879-017-2414-9.
4
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).头孢洛扎/他唑巴坦对欧洲和美国医院腹腔内和尿路感染分离的需氧革兰氏阴性菌的活性检测（2012 年）。
J Infect. 2014 Sep;69(3):266-77. doi: 10.1016/j.jinf.2014.04.004. Epub 2014 Apr 26.
5
Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.头孢洛扎/他唑巴坦用于治疗复杂性腹腔内感染。
Expert Opin Pharmacother. 2015 Feb;16(2):271-80. doi: 10.1517/14656566.2015.994504. Epub 2014 Dec 22.
6
Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.2012 年至 2016 年间，作为全球监测计划的一部分，从美国和欧洲的儿科患者中收集革兰氏阴性分离株，对头孢洛扎他唑巴坦和对照药物进行检测的活性。
Int J Antimicrob Agents. 2019 May;53(5):637-643. doi: 10.1016/j.ijantimicag.2019.01.015. Epub 2019 Feb 1.
7
Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.基于英国细菌分离株的体外监测，比较头孢洛扎/他唑巴坦联合甲硝唑与哌拉西林/他唑巴坦作为经验性治疗复杂腹腔内感染的成本效益。
J Med Econ. 2017 Aug;20(8):840-849. doi: 10.1080/13696998.2017.1333960. Epub 2017 Jun 8.
8
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.头孢洛扎/他唑巴坦：一种新型头孢菌素与β-内酰胺酶抑制剂的组合。
Ann Pharmacother. 2015 Sep;49(9):1046-56. doi: 10.1177/1060028015593293. Epub 2015 Jul 9.
9
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).头孢洛扎/他唑巴坦联合甲硝唑用于多重耐药时代复杂性腹腔内感染的治疗：一项随机、双盲、3期试验（ASPECT-cIAI）的结果
Clin Infect Dis. 2015 May 15;60(10):1462-71. doi: 10.1093/cid/civ097. Epub 2015 Feb 10.
10
Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016.亚太地区下呼吸道感染分离的革兰氏阴性病原菌对头孢他洛滨-他唑巴坦的活性：SMART 2015-2016。
Int J Antimicrob Agents. 2020 Mar;55(3):105883. doi: 10.1016/j.ijantimicag.2020.105883. Epub 2020 Jan 8.

引用本文的文献

1
Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns.两名全身大面积烧伤患者持续输注头孢洛扎/他唑巴坦的药代动力学
Pharmacotherapy. 2025 Jun;45(6):386-392. doi: 10.1002/phar.70019. Epub 2025 Apr 15.
2
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.攻克外膜：促进化合物进入革兰氏阴性菌病原体。
NPJ Antimicrob Resist. 2023 Dec 20;1(1):17. doi: 10.1038/s44259-023-00016-1.
3
Molecular characterization of clinically isolated with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021.2020 年至 2021 年期间，作为 ATLAS 全球监测计划的一部分收集了具有不同头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦耐药性的临床分离株，并对其进行了分子特征分析。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0067024. doi: 10.1128/aac.00670-24. Epub 2024 Sep 10.
4
Emerging challenges in antimicrobial resistance: implications for pathogenic microorganisms, novel antibiotics, and their impact on sustainability.抗菌药物耐药性的新挑战：对病原微生物、新型抗生素及其对可持续性影响的意义。
Front Microbiol. 2024 Apr 29;15:1403168. doi: 10.3389/fmicb.2024.1403168. eCollection 2024.
5
In Vitro Activity of Ceftolozane-Tazobactam against , and Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa.头孢他啶阿维巴坦对从南非哨点公立医院血培养中分离出的[具体细菌名称缺失]、[具体细菌名称缺失]和[具体细菌名称缺失]的体外活性
Antibiotics (Basel). 2023 Feb 24;12(3):453. doi: 10.3390/antibiotics12030453.
6
Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections.头孢他啶阿维巴坦与最佳替代疗法对多重耐药和广泛耐药铜绿假单胞菌下呼吸道感染患者临床结局的影响
Infect Dis Ther. 2022 Oct;11(5):1965-1980. doi: 10.1007/s40121-022-00687-9. Epub 2022 Sep 1.
7
Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.比较头孢他啶/他唑巴坦输注方案在中空纤维感染模型中对广泛耐药铜绿假单胞菌分离株的疗效。
Microbiol Spectr. 2022 Jun 29;10(3):e0089222. doi: 10.1128/spectrum.00892-22. Epub 2022 Jun 13.
8
Evaluation of Carbapenem Use Before and After Implementation of an Antimicrobial Stewardship-Led Carbapenem-Sparing Strategy in a Lebanese Tertiary Hospital: A Retrospective Study.在黎巴嫩一家三级医院实施抗菌药物管理主导的碳青霉烯类药物节约策略前后碳青霉烯类药物使用的评估：一项回顾性研究。
Front Cell Infect Microbiol. 2022 Mar 25;12:729491. doi: 10.3389/fcimb.2022.729491. eCollection 2022.
9
Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.在中空纤维感染模型中，头孢他啶/他唑巴坦连续输注浓度对广泛耐药铜绿假单胞菌分离株的影响。
Sci Rep. 2021 Nov 12;11(1):22178. doi: 10.1038/s41598-021-01784-4.
10
Ceftolozane-tazobactam- and ceftazidime-avibactam-resistant mastoiditis.对头孢洛扎-他唑巴坦和头孢他啶-阿维巴坦耐药的乳突炎
Access Microbiol. 2020 Jan 20;2(2):acmi000092. doi: 10.1099/acmi.0.000092. eCollection 2020.

本文引用的文献

1
Vaccine approaches for multidrug resistant Gram negative infections.针对多重耐药革兰氏阴性感染的疫苗方法。
Curr Opin Immunol. 2014 Jun;28:84-9. doi: 10.1016/j.coi.2014.02.002. Epub 2014 Mar 15.
2
Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.肾功能对头孢洛扎-他唑巴坦药代动力学及安全性的影响
Antimicrob Agents Chemother. 2014;58(4):2249-55. doi: 10.1128/AAC.02151-13. Epub 2014 Feb 3.
3
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.头孢洛扎他唑巴坦：一种新型头孢菌素/β-内酰胺酶抑制剂组合，对多种耐药性革兰氏阴性杆菌具有活性。
Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2.
4
Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination.头孢他啶/阿维巴坦：一种新型抗假单胞菌头孢菌素与β-内酰胺酶抑制剂的组合。
Infect Drug Resist. 2013 Nov 29;6:215-23. doi: 10.2147/IDR.S36140.
5
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.10 x '20 进展——开发针对革兰氏阴性杆菌的新型药物：来自美国传染病学会的最新进展。
Clin Infect Dis. 2013 Jun;56(12):1685-94. doi: 10.1093/cid/cit152. Epub 2013 Apr 17.
6
Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.铜绿假单胞菌临床分离株中泛β-内酰胺类耐药的发展：分子机制、青霉素结合蛋白谱和结合亲和力。
Antimicrob Agents Chemother. 2012 Sep;56(9):4771-8. doi: 10.1128/AAC.00680-12. Epub 2012 Jun 25.
7
Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.健康成年受试者单剂量和多剂量静脉滴注头孢他洛滨-他唑巴坦的药代动力学和安全性。
Antimicrob Agents Chemother. 2012 Jun;56(6):3086-91. doi: 10.1128/AAC.06349-11. Epub 2012 Mar 26.
8
Acquired antibiotic resistance genes: an overview.获得性抗生素耐药基因：概述。
Front Microbiol. 2011 Sep 28;2:203. doi: 10.3389/fmicb.2011.00203. eCollection 2011.
9
Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.CXA-101 是一种新型头孢菌素，与他唑巴坦联合测试对具有不同耐药表型的肠杆菌科、铜绿假单胞菌和脆弱拟杆菌菌株的抗菌活性。
Antimicrob Agents Chemother. 2011 May;55(5):2390-4. doi: 10.1128/AAC.01737-10. Epub 2011 Feb 14.
10
Progress and challenges in implementing the research on ESKAPE pathogens.ESKAPE 病原体研究实施的进展与挑战。
Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S7-10. doi: 10.1086/655995.

头孢他啶/他唑巴坦：治疗复杂性革兰氏阴性菌感染的新选择。

Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.

作者信息

Sorbera Maria, Chung Elizabeth, Ho Christopher W, Marzella Nino

出版信息

P T. 2014 Dec;39(12):825-32.

PMID:25516692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4264669/
Abstract

Ceftolozane/tazobactam: a new option in the treatment of complicated gram-negative infections.

摘要

头孢他啶/他唑巴坦：治疗复杂性革兰氏阴性菌感染的新选择。